Apichope Pharmaceutical Group (300723.SZ) Obtains Registration Certificate for Esomeprazole Magnesium Enteric Dry Suspension

Stock News11-28

Apichope Pharmaceutical Group Co., Ltd. (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Apichope Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for Esomeprazole Magnesium Enteric Dry Suspension issued by the National Medical Products Administration. Esomeprazole is a proton pump inhibitor and the S-isomer of omeprazole. It specifically inhibits the H+-K+ ATPase in gastric parietal cells, blocking the final step of gastric acid secretion. Esomeprazole converts into its active form in the acidic environment of gastric parietal cells, effectively suppressing both basal and stimulated gastric acid secretion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment